Commentary: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo - Top-Institutions - MDSpire

Commentary: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo

  • By

  • Yang Yu

  • Liang Zhan

  • Zhenzhen Tang

  • June 5, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Gastroenterology
    • IBD

  • #2

    Cedars-Sinai Medical Center
    Cedars-Sinai Medical Center

    Los Angeles, California

    Key Differentiators

    • Gastroenterology
    • IBD

Original Source(s)

Commentary: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo

  • by Yang Yu, Liang Zhan, Zhenzhen Tang

  • June 5, 2026

Related Content

Sex-related peripheral immune profile in ulcerative colitis: links to fatigue

Macrophage dysregulation in inflammatory bowel disease: cellular heterogeneity, pathogenic mechanism, and treatment

Renal Conditions Associated with Inflammatory Bowel Disease: Exploring Clinical Links, Shared Mechanisms, and Management Approaches